Monoclonal antibodies
Accelerate your monoclonal antibody (mAb) development and manufacturing with our proprietary continuous bioprocess manufacturing platform, EnzeneXTM.
Why develop mAbs?
The high specificity, affinity and reproducibility of mAbs ensure accurate and consistent targeting of specific antigens, making them effective therapeutic agents. This class of biologics have revolutionized the treatment of various diseases, including cancer, infectious diseases and autoimmune disorders. Their ability to precisely target disease-associated molecules minimizes side effects and improves patient outcomes.
Understanding our mAb solutions
We have experience in successfully commercializing mAbs, and have commercialized several biosimilar mAb products, including:
| mAb | Disease target |
|---|---|
| Denosumab | Human IgG2 mAb used for the treatment of postmenopausal osteoporosis of giant cell tumor of bone. |
| Adalimumab | Human IgG1 mAb which targets human tumor necrosis factor (TNF) for the treatment of rheumatoid arthritis. |
| Cetuximab | Chimeric IgG1 mAb for the treatment of squamous cell cancer of the head and neck |
| Bevacizumab | Humanized IgG1 mAb for treating metastatic colorectal cancer |
| Ranibizumab | Humanized mAb fragment and a recombinant humanized IgG1 isotope which bind and inhibit to treat neovascular (wet) age-related macular degeneration. |
We can take your product from cell line to finish line using our fed-batch approach, or by harnessing our patented and validated continuous bioprocess manufacturing platform, EnzeneXTM.
This continuous method has been critical for monoclonal antibody manufacturing, helping to increase productivity and maintain high quality while providing cost-efficiency.
Why partner with Enzene for mAbs?
We are a global CDMO and biosimilar developer dedicated to impacting the global healthcare landscape by bringing trusted and affordable medicines to market, quickly.
We understand that each modality has unique requirements, and we are committed to providing you with the highest quality products and services. Our flexible development and manufacturing platforms allow us to quickly and efficiently produce modalities, regardless of their complexity or scale.
Our proprietary continuous bioprocess manufacturing platform, EnzeneX™ further enhances production, with accelerated rates and a significant reduction in the cost of producing complex modalities — from mAbs to complex proteins.
Related case studies
Latest resources
A modality for every need
Fueled by our continuous innovation and armed with our wide variety of modalities, we are dedicated to bringing your biologics innovations to life.